Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 8/20 | 0.35 |
| ▸ | CA2 | P00918 | 8/20 | 0.35 |
| ▸ | CA12 | O43570 | 6/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569003 | 0.91 | SERPINE1 (0.43) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL25189025 | 0.86 | SYK (0.43) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL10029064 | 0.86 | SYK (0.43) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL18361449 | 0.86 | SYK (0.43) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL15876421 | 0.85 | SERPINE1 (0.40) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL26774025 | 0.85 | SERPINE1 (0.40) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL2860412 | 0.85 | MEN1 (0.42) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL23674564 | 0.84 | SERPINE1 (0.41) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL14726004 | 0.84 | TDP1 (0.43) | SERPINE1MEN1GAAKMT2ATDP1 | |
| SCHEMBL23792183 | 0.82 | SERPINE1 (0.38) | SERPINE1MEN1GAAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106082-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021585-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | SERPINE1 246/4885MEN1 2376/4885GAA 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.